Sad_老虎社区_美港股上老虎

Sky0501
2021-06-18

Sad

Low dosage may be behind low efficacy of CureVac vaccine: Study leader

BERLIN (REUTERS) - The low dosage might be a key reason why CureVac's Covid-19 vaccine reported disa

Low dosage may be behind low efficacy of CureVac vaccine: Study leader

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":168164964,"tweetId":"168164964","gmtCreate":1623966690558,"gmtModify":1634025229688,"author":{"id":3573257474509177,"idStr":"3573257474509177","authorId":3573257474509177,"authorIdStr":"3573257474509177","name":"Sky0501","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Sad</p></body></html>","htmlText":"<html><head></head><body><p>Sad</p></body></html>","text":"Sad","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/168164964","repostId":2144744636,"repostType":4,"repost":{"id":"2144744636","kind":"news","pubTimestamp":1623940250,"share":"https://www.laohu8.com/m/news/2144744636?lang=&edition=full","pubTime":"2021-06-17 22:30","market":"us","language":"en","title":"Low dosage may be behind low efficacy of CureVac vaccine: Study leader","url":"https://stock-news.laohu8.com/highlight/detail?id=2144744636","media":"The Straits Times","summary":"BERLIN (REUTERS) - The low dosage might be a key reason why CureVac's Covid-19 vaccine reported disa","content":"<div>\n<p>BERLIN (REUTERS) - The low dosage might be a key reason why CureVac's Covid-19 vaccine reported disappointing efficacy in a pivotal late-stage trial, the scientist leading the study of the shot said ...</p>\n\n<a href=\"http://www.straitstimes.com/world/europe/low-dosage-may-be-behind-low-efficacy-of-curevac-vaccine-study-leader\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Low dosage may be behind low efficacy of CureVac vaccine: Study leader</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLow dosage may be behind low efficacy of CureVac vaccine: Study leader\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 22:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/world/europe/low-dosage-may-be-behind-low-efficacy-of-curevac-vaccine-study-leader><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BERLIN (REUTERS) - The low dosage might be a key reason why CureVac's Covid-19 vaccine reported disappointing efficacy in a pivotal late-stage trial, the scientist leading the study of the shot said ...</p>\n\n<a href=\"http://www.straitstimes.com/world/europe/low-dosage-may-be-behind-low-efficacy-of-curevac-vaccine-study-leader\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CVAC":"CureVac B.V."},"source_url":"http://www.straitstimes.com/world/europe/low-dosage-may-be-behind-low-efficacy-of-curevac-vaccine-study-leader","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2144744636","content_text":"BERLIN (REUTERS) - The low dosage might be a key reason why CureVac's Covid-19 vaccine reported disappointing efficacy in a pivotal late-stage trial, the scientist leading the study of the shot said on Thursday (June 17).\nThe German biotech's vaccine proved only 47 per cent effective in an initial trial, far lower than those of rivals BioNTech/Pfizer and Moderna, which are also based on mRNA technology and had efficacy rates well above 90 per cent.\nDr Peter Kremsner from the University Hospital in Tuebingen which is running the trial, told Reuters the low efficacy is \"very likely due to the dose\".\nUnlike BioNTech and Moderna, CureVac did not modify the mRNA used in the shots and therefore a higher dosage was not possible because of the side effects to be expected, Dr Kremsner said.\nWith just 12 micrograms of mRNA per dose, the company has been seeking to position itself as a low-dose alternative to BioNTech and Moderna's established shots with 30 and 100 micrograms per shot, respectively.\nIt is also easy to store and cheaper than the other mRNA shots too.\nThe European Union has agreed to pay 12 euros (S$19.20) per dose for supplies of the shot, an EU internal document shows, but has paid more than 15 euros for the other mRNA shots.\nHowever, the interim trial analysis goes some way to challenging the expectation, which was previously reflected in the company's share price, that all mRNA vaccines are similar.\nThe news wiped as much as 52 per cent off the company's value on Thursday.\nCureVac said on Wednesday that new variants had proved a headwind, but data from BioNTech and Moderna have, however, so far suggested only somewhat weaker protection against new variants.\nDr Kremsner said he thought it was probably a \"long shot\" as to whether CureVac's vaccine might turn out to be more effective when targeting a particular variant.\nThe disappointing results are a blow since European governments had been hoping to add it to their arsenal after age limits were imposed on the use of the Johnson & Johnson and AstraZeneca vaccines due to a link to extremely rare but potentially fatal clotting disorders.","news_type":1},"isVote":1,"tweetType":1,"viewCount":513,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":3,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}